About
Pipeline
Antibiotic Resistance
Blog
Investors & Media
Partners
Careers
Contact

Spero Therapeutics: Remodeling Antibiotics

Spero Therapeutics: Remodeling Antibiotics

Posted on December 17, 2015 at 12:49 am.

Written by Spero Therapeutics

Post navigation

Drug industry warming to antibiotics, but resistance outpaces new products

Spero Therapeutics Licenses Dihydrofolate Reductase Inhibitors from Promiliad Biopharma

Recent Posts

PASTEUR Act Reintroduced – A Bold, Potentially Transformative Approach to Addressing the Threat of Antimicrobial Resistance
COVID-19 Has Made Hospital Avoidance a Critical Component of Good Care
SPR720: Listening to patients, clinicians and regulators, and advancing forward
Evidence Matters: Importance of Tebipenem HBr Oral-Only Trial Design for Clinical Utility and Commercial Uptake Potential
Beyond the headlines: Why we are excited about our pipeline and the future for patients needing effective treatments for infections

Categories

Categories

Archives

Archives

About
Management Team
Board of Directors
Contact

Pipeline
Tebipenem HBr: Oral Gram-Negative Program
SPR720: Nontuberculous Mycobacterium
SPR206: Direct Acting IV Potentiator
Key Publications and Presentations

Antibiotic Resistance

Partners

Investors & Media
Overview
News Releases
Spero in the News
Events & Presentations
Stock Information
Corporate Governance
SEC Filings
IR Resources

Careers

©2022 Spero Therapeutics All Rights Reserved

Privacy Policy
Terms of Use